Pioneering Cerebrovascular Cell Therapy for Over Two Decades
Somata Genesis has spent more than 20 years advancing cerebrovascular administration of cellular biologics — pushing regenerative medicine into territory that conventional drug therapies can’t reach. Since 2011, we’ve studied both autologous (a patient’s own cells) and allogeneic (donor-derived) multipotent cellular products through a sustained clinical trial program, using cath lab-guided selective administration to deliver treatments with precision.
Alongside our own research, we partner with sponsors across the USA, UK, and Europe to provide contract research services. Since expanding into this work in 2015, we’ve maintained strict compliance with industry standards while building proprietary technologies that strengthen integrity checkpoints across clinical research and bioavailability/bioequivalence (BA/BE) studies.
Our Approach
Regenerative medicine works differently than conventional pharmaceuticals. Drug molecules act systemically, producing effects only after they’re metabolized. Cellular products behave differently — they interact with the body, undergo biochemical transformation, and begin driving biological processes almost immediately, with effects concentrated locally rather than system-wide.
That distinction shapes everything we do. The specific cellular products we use, how they behave in a given condition, and how precisely they’re delivered all directly determine safety and outcomes. Our research has focused on understanding how autologous and allogeneic transplants differ in immunogenicity, proliferation, differentiation, and the biological processes they trigger — and we’ve developed proprietary techniques to help our cellular biologics withstand the osmotic and pH stresses of the in vivo environment.
Our Track Record
2011 — As Genesis Limited, we launched our first multicenter clinical trial pilot, studying how autologous hematopoietic cells could induce angiogenesis in patients with Multiple Sclerosis. This four-year study (IECP/27/2011), overseen by the Independent Ethics Committee in Pune, laid the foundation for the cerebrovascular intervention techniques that remain benchmarks in treating specific ischemic brain injuries today.
2015 — We expanded the program internationally (ClinicalTrials.Gov: NCT02418325 / PRT/GENESIS/2015/001), studying allogeneic human umbilical cord-derived mesenchymal stromal cells (UC-MSC) alongside liberation therapy for patients with Relapsing-Remitting Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency (CCSVI). The study has now been consolidated in India for tighter control over participant screening, in line with regulations governing international clinicians’ involvement in cross-border trials. That January, the Independent Ethics Committee Pune approved the twin studies PRT/GENESIS/2015/001 and PRT/GENESIS/2015/002 — run concurrently over five years to assess autologous and allogeneic cellular glycoprotein variants side by side. Studying both simultaneously, rather than sequentially, let us establish NEDA and PIRA benchmarks across a 14-subject pilot cohort.
That work has informed a biomarker-guided inclusion framework we’ve proposed for B-cell depletion and chemotherapeutic escalation in Multiple Sclerosis care.
Throughout, we’ve reported zero adverse events — a record we consider foundational to earning trust in an emerging field.
Where We Work
Somata Genesis Incorporated (formerly Genesis Limited) now operates across four countries. In the U.S., we were the first company to build collaborative relationships within the health insurance sector to pursue clinical trial coverage for our Multiple Sclerosis biologic, Neutrojen, under the Right to Try Act of 2018.
Our India-based subsidiary, Somata Genesis Biotech Pvt. Ltd., draws on the country’s cost-effective clinical research infrastructure and manufacturing capabilities, working alongside experienced local surgeons and scientists to develop protocols that would be difficult to replicate elsewhere. We’re currently building an all-in-one research and medical facility on India’s west coast to bring this work under one roof.
About the founder
Surjo Banerjee founded Somata Genesis to take on some of medicine’s most stubborn problems — conditions where existing treatments manage symptoms but don’t address root causes. His focus on cerebral insufficiency has driven the company’s exploration of the vascular links underlying neurological disease.